News
Tome Bio founders wrangle ‘jumping genes’ to create new programmable gene insertion tool
Scientists develop STITCHR, a retrotransposon-based gene editing tool, by Omar Abudayyeh (Mass General Brigham) and Jonathan ...
Under the 11-page 'roadmap' outlined Thursday, the goal is for animal testing to become 'the exception rather than the norm' ...
After 17 years at Genentech, Ira Mellman is joining the Parker Institute for Cancer Immunotherapy as president of research.
Trump signals imminent pharma tariffs, with experts including Mollie Sitkowski of Faegre Drinker suggesting 25% levy possible ...
VC execs write to Sen. Cassidy about FDA staffing concerns, citing delays & uncertainties due to loss of experienced staff & ...
Alzheon's valiltramiprosate (ALZ-801) fails Phase 3 trial in Alzheimer's patients with APOE4 gene copies, showing no ...
Researchers at AAN meeting discuss myasthenia gravis advances as J&J reports long-term data for nipocalimab, while argenx's ...
RFK Jr.'s first TV interview as HHS head reveals vaccine skepticism, support for measles shots, Novavax concerns, HHS cuts, ...
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Bristol Myers Squibb’s combined immunotherapies Opdivo and Yervoy won approval this week as a first-line treatment for ...
CDMOs fear that FDA site inspections might slow down due to the mass staffing cuts at the federal health agencies.
A biotech incubated by RA Capital has secured a $57.5 million Series B to begin a mid-stage trial for its cardio drug this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results